ArticleCell reports2021
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 73 citations in OpenAlex.
- Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.Cancer research · 2024Trial
- Article
- Biology and function of the autotaxin/lysophosphatidic acid axis in cancer (Review).Molecular and clinical oncology · 2026Review
- LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.Science advances · 2026Article
- Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer.Cancer immunology research · 2026Article
- Identification of potential biomarkers and therapeutic targets for liver cirrhosis based on Mendelian randomization and machine learning.Biochemistry and biophysics reports · 2026Article
- Metabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy.Experimental & molecular medicine · 2026Review
- Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8The American journal of pathology · 2026Article
- GLUT1 expression, lymphocyte distribution and CD3Journal of experimental & clinical cancer research : CR · 2026Article
- Lpar5 regulates the CD8 T-cell response to persistent virus infection by altering exhaustion programming, survival, and NK receptor expression.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks.Signal transduction and targeted therapy · 2025Review
- In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors.bioRxiv : the preprint server for biology · 2025Article
- How does lipid phosphatase 1 (LPP1) regulate antitumor CD8Immunity · 2025Article
- Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma.Nature communications · 2025Article
- Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.Molecular cancer therapeutics · 2025Article
- Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy.International journal of molecular sciences · 2025Article
- AGPAT3 Regulates Immune Microenvironment in Osteosarcoma via Lysophosphatidic Acid Metabolism.Oncology research · 2025Article
- Identification of sex- and inflammation-associated heterogeneity in the mouse omentum.Frontiers in immunology · 2025Article
- LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10.Acta pharmacologica Sinica · 2025Article
- Deleting autotaxin in LysM+ myeloid cells impairs innate tumor immunity in models of metastatic melanoma.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Elisa Matas-RicoDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: ematas@uma.es.
Elselien FrijlinkDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Irene van der Haar ÀvilaDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Apostolos MenegakisOncode Institute, Utrecht, the Netherlands; Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Maaike van ZonDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Andrew J MorrisDivision of Cardiovascular Medicine, Gill Heart Institute and Lexington Veterans Affairs Medical Center, University of Kentucky, Lexington, KY, USA.
Jan KosterLaboratory for Experimental Oncology and Radiobiology, Amsterdam UMC, Amsterdam, the Netherlands.
Fernando Salgado-PoloDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Sander de KivitDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Telma LançaOncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Antonio MazzoccaInterdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
Zoë JohnsoniOnctura SA, Campus Biotech Innovation Park, Geneva, Switzerland.
John HaanenDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ton N SchumacherOncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Anastassis PerrakisDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Inge VerbruggeDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Joost H van den BergDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jannie BorstDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: j.g.borst@lumc.nl.
Wouter H MoolenaarDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: w.moolenaar@nki.nl.
The Netherlands Cancer Institute · NLAmsterdam University Medical Centers · NLUniversity of Bari Aldo Moro · ITUniversity of Kentucky · US
Funding
Pilot Projects ProgramP30GM127211 · NIGMS · UNIVERSITY OF KENTUCKY · PI PEARSON, KEVIN JOSEPH · 2018 to 2022
$5.7MLipid phosphate phosphatase 3 as a novel atherosclerosis suppressorR01HL120507 · NHLBI · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J, SMYTH, SUSAN S. · 2015 to 2018
$2.1MLysophosphatidic Acid and Cardiovascular Disease RiskI01BX005637 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J, SMYTH, SUSAN S. · 2021 to 2024
–Lysophosphatidic acid and cardiovascular disease riskI01CX001550 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J · 2017 to 2021
–BLRD VA I01 BX005637CSRD VA I01 CX001550NHLBI NIH HHS R01 HL120507NIGMS NIH HHS P30 GM127211
Abstract
Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and T cell motility via LPAR2, yet its actions in the tumor immune microenvironment remain unclear. Here, we show that ATX secreted by melanoma cells is chemorepulsive for tumor-infiltrating lymphocytes (TILs) and circulating CD8
Indexed as
AnimalsCD8-Positive T-LymphocytesCell Line, TumorChemotaxisFemaleHumansLymphocytes, Tumor-InfiltratingLysophospholipase DLysophospholipidsMiceMice, Inbred C57BLNeoplasmsPhosphoric Diester HydrolasesReceptors, Lysophosphatidic AcidSignal TransductionTumor Microenvironmentlysophosphatidic acidLysophospholipase DLysophospholipidsPhosphoric Diester HydrolasesReceptors, Lysophosphatidic Acidanti-cancer vaccinationautotaxinchemorepulsionG protein-coupled receptorsimmunotherapylysophosphatidic acidmelanomasingle-cell RNAseqT cellstumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.